Molecules · 2015 · 13 citations · 20 references
PharmacyMedicinal ChemistryPharmacologyCardiovascular PharmacotherapyDrug DiscoveryHemostasisAntiplatelet TherapyAntithrombotic TherapyPlatelet ActivationPlatelet AggregationThromboembolism PreventionThrombosis PreventionAntiplatelet DrugsPharmacologic ThromboprophylaxisPlatelet Aggregation InhibitionPlatelet InhibitionThrombotic Platelet AggregationThrombotic Risk Reduction
Thrombosis is the main outcome of many cardiovascular diseases. Current treatments to prevent thrombotic events involve the long-term use of antiplatelet drugs. However, this therapy has several limitations, thereby justifying the development of new drugs. A series of N-oxide derivatives (furoxan and benzofuroxan) were synthesized and characterized as potential antiplatelet/antithrombotic compounds. All compounds (3a,b, 4a,b, 8a,b, 9a,b, 13a,b and 14a,b) inhibited platelet aggregation induced by adenosine-5-diphosphate, collagen, and arachidonic acid. All compounds protected mice from pulmonary thromboembolism induced by a mixture of collagen and epinephrine; however, benzofuroxan derivatives (13a,b and 14a,b) were the most active compounds, reducing thromboembolic events by up to 80%. N-oxide derivative 14a did not induce genotoxicity in vivo. In conclusion, 14a has emerged as a new antiplatelet/antithrombotic prototype useful for the prevention of atherothrombotic events.
20
The aggregation of blood platelets
G. V. R. Born, Michael Cross · The Journal of Physiology · 1963 · 2.1K citations
Medicine, Cell Biology, Hematology +12
Aspirin-like Molecules that Covalently Inactivate Cyclooxygenase-2
Amit S. Kalgutkar, Brenda C. Crews, Scott W. Rowlinson et al. · Science · 1998 · 261 citations
Hankey Graeme J, Eikelboom John W, 杨靓 et al. · 2004 · 234 citations